September 2026 brings a major private Depo-Provera settlement process, continuing litigation over unresolved claims, and two nationwide drug recalls. The key takeaway is that official September mass-tort totals are not yet available, while court filings and agency notices still require prompt attention. Multidistrict litigation, or MDL, consolidates similar federal lawsuits before one judge for coordinated pretrial proceedings. It does not automatically create a class action or guarantee that every claimant receives the same result.
Table of Contents
- Why September MDL totals remain uncertain
- What changed in the Depo-Provera litigation?
- Which Depo-Provera issues are still unresolved?
- Which other pharmaceutical MDLs deserve attention?
- What do September FDA notices mean for patients?
Why September MDL totals remain uncertain
As of September 7, the U.S. Judicial Panel on Multidistrict Litigation had not posted its September quarterly caseload report. Its quarterly summary page listed September 2026 but still linked only the March and June reports.
The latest official snapshot therefore remains June 30. It counted 3,848 GLP-1 injury actions, 146 GLP-1 vision-loss or NAION actions, and 1,832 Suboxone film actions. Those figures confirm that each proceeding entered September with substantial federal caseloads. They should not be presented as current September counts because filings, transfers, dismissals, and settlements may have changed the totals.
What changed in the Depo-Provera litigation?
The Depo-Provera mdl had 6,289 member actions by July 27. New filings continued after plaintiffs' leadership announced a settlement covering most federal and New York claims, although they arrived at a greatly reduced rate. The agreement was estimated to cover roughly 80% of MDL plaintiffs.
According to the court's Case Management Order No. 12, registration was anticipated in November 2026, with payments expected during the first quarter of 2027. This is a private, confidential settlement rather than a class settlement. It is not subject to a class-action fairness determination, so the public record does not provide a court-approved recovery schedule for every claimant.
Which Depo-Provera issues are still unresolved?
The court scheduled a September 18 hearing on general causation and Rule 702 motions. General causation asks whether the product can cause the alleged injury, while Rule 702 governs whether expert testimony is reliable enough to be admitted.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
The court also selected three replacement pilot cases for expedited statute-of-limitations litigation. Those proceedings may be especially important for settlement opt-outs and people who are ineligible for the agreement. Affected claimants should verify:.
- Whether their case falls within the private settlement.
- What registration or response deadlines apply.
- Whether opting out preserves a viable individual claim.
- Whether a filing deadline or statute-of-limitations defense affects the case.
Which other pharmaceutical MDLs deserve attention?
The June 30 JPML report shows that GLP-1 injury, GLP-1 vision-loss, and Suboxone film litigation remained large federal proceedings entering September. Their separate counts also show why readers should not treat every allegation involving the same drug category as one consolidated docket. Dupixent litigation is at a much earlier stage.
The JPML's June 30 report listed 26 pending actions in the recently created products-liability MDL. That makes Dupixent a developing proceeding, not a mature mass tort. Early case counts reveal little about eventual eligibility standards, expert rulings, trial selections, or settlements.
What do September FDA notices mean for patients?
On September 1, the FDA required Injectafer labeling to include a boxed warning about symptomatic low phosphate. Reports continued despite earlier labeling changes, and the agency recommends phosphate monitoring for at-risk patients and those receiving repeat treatment within three months. Two nationwide recalls followed on September 3. B. Braun recalled three lots of 0.9% sodium-chloride injection after finding iron oxide and other particulate matter.
No serious injuries or deaths had been reported, but the company warned of potentially life-threatening vascular and organ effects. American Regent also recalled three lots of multi-dose epinephrine injection because cracked or leaking vials compromised sterility and contained particulate matter. The FDA recall notice instructed affected facilities and users to stop using the product and return or discard it. Anyone who may have received an affected product should preserve the drug name, lot information, treatment date, medical records, and related bills. Do not stop or replace prescribed treatment without contacting a qualified healthcare professional.
You Might Also Like
- What Is New With Demographic Guides Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Defendants Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Comparisons Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways